
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
FHI Clinical Inc. has announced it has partnered with Infectious Disease Research Institute (IDRI) to provide full-service contract research organization capabilities for an immunotherapy clinical trial to combat moderate to severe cases of COVID-19. IDRI recently received funding from Celularity launch a clinical trial to investigate the use of Celularity’s NK cell therapy, currently under study for the treatment as a potential treatment option against the novel coronavirus.
For more information, click






